Amyloid-beta-binding Peptides and the Use Thereof for the Therapy and Diagnosis of Alzheimer's Dementia

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes novel peptides that specifically bind to amyloid-beta species found in the brains of Alzheimer's disease patients. By modifying the ends of these peptides (especially at the C-terminus) and designing them with special amino acid sequences (often using D-enantiomers for better stability and function), these peptides show increased binding affinity and effectiveness in targeting, neutralizing, or removing toxic amyloid-beta oligomers, fibrils, and aggregates. These peptides can be used both therapeutically (to treat or prevent Alzheimer's disease) and diagnostically (as probes for early and specific Alzheimer's detection).

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of Alzheimer's disease by administering these peptides to reduce or neutralize toxic amyloid-beta aggregates in patients' brains.
• Early diagnosis of Alzheimer's disease via imaging agents or diagnostic kits containing these peptides that can specifically identify amyloid-beta aggregates.
• Prevention of Alzheimer's disease progression in high-risk individuals, by inhibiting early formation of amyloid-beta oligomers and plaques.
• Development of vaccines, injectable solutions, or oral medications containing these peptides.
• Ex vivo treatments for blood, blood products, or organs to remove toxic amyloid-beta species.
• Use in pharmaceutical kits for clinical or laboratory purposes.
• Use as imaging probes in PET, MRI, SPECT, or fluorescence imaging for research or clinical diagnosis.

BenefitsContent extracted from patent full text and abstract with AI.

• Higher binding affinity and specificity to toxic amyloid-beta species compared to previously known peptides, increasing therapeutic and diagnostic effectiveness.
• Reduced likelihood of unwanted immune responses due to the peptide design.
• Ability to neutralize and eliminate not only monomers but also toxic oligomers and fibrils, addressing key contributors to Alzheimer's pathology.
• Potential for earlier, more accurate diagnosis of Alzheimer's disease before symptom onset, enabling earlier intervention.
• Enhanced resistance to degradation in the body by using D-amino acids or cyclized structures, leading to improved stability and longevity in therapeutic or diagnostic applications.
• Broader applicability: peptides can be formulated for different uses, such as drugs, vaccines, diagnostic probes, or research reagents.
• Demonstrated improved effectiveness in animal models, supporting their clinical potential.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to amyloid-beta-binding peptides and the use thereof for the therapy and diagnosis of Alzheimer's dementia.